Exemestane Plus Ovarian Function Suppression Is the Best Adjuvant Treatment of Premenopausal Women With Endocrine-Responsive Breast Cancer at Higher Risk of Relapse and With HER2-Negative Tumors

J Clin Oncol. 2019 Jul 20;37(21):1838-1840. doi: 10.1200/JCO.19.00559. Epub 2019 Jun 7.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Androstadienes
  • Breast Neoplasms*
  • Female
  • Humans
  • Neoplasm Recurrence, Local
  • Premenopause

Substances

  • Androstadienes
  • exemestane